Last €0.19 EUR
Change Today -0.008 / -4.10%
Volume 1.4M
BTH1V On Other Exchanges
Symbol
Exchange
Helsinki
Berlin
OTC US
As of 11:29 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

biotie therapies oyj (BTH1V) Snapshot

Open
€0.19
Previous Close
€0.20
Day High
€0.19
Day Low
€0.18
52 Week High
02/3/14 - €0.33
52 Week Low
08/13/14 - €0.18
Market Cap
85.3M
Average Volume 10 Days
344.8K
EPS TTM
€0.0012
Shares Outstanding
456.0M
EX-Date
03/30/06
P/E TM
151.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIE THERAPIES OYJ (BTH1V)

Related News

No related news articles were found.

biotie therapies oyj (BTH1V) Related Businessweek News

No Related Businessweek News Found

biotie therapies oyj (BTH1V) Details

Biotie Therapies Corp. operates as a drug development company. It focuses on the development of drugs for neurodegenerative and psychiatric disorders, such as Parkinson’s disease, Alzheimer’s disease and other cognitive disorders, alcohol and drug dependence (addiction), and post-traumatic stress disorder; and inflammatory and fibrotic liver diseases. The company has a development portfolio with various small molecule and biological drug candidates at various stages of clinical development. Its advanced product, Selincro (nalmefene) reduces alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. The company’s drug development projects also include Tozadenant (SYN115), an oral, potent, and selective adenosine A2a receptor antagonist in Phase 3 development, which enters the brain and modulates regions associated with motor and non-motor function; SYN120, an oral, potent, and selective antagonist of the 5-HT6 receptor, which has completed single and multiple ascending dose Phase 1 clinical studies and a Phase 1 positron emission tomography imaging study to determine therapeutic dose; and BTT-1023 (VAP-1 antibody) that has completed Phase Ib clinical trials for the treatment of rheumatoid arthritis and psoriasis. In addition, its drug development projects comprise Nepicastat (SYN117), a cocaine dependence enzyme dopamine beta hydroxylase inhibitor focusing on conducting Phase 2 clinical trial; and Ronomilast, an oral phosphodiesterase-4 inhibitor with therapeutic potential in chronic inflammatory disorders. The company has strategic collaboration with UCB Pharma S.A. Biotie Therapies Corp. is based in Turku, Finland.

35 Employees
Last Reported Date: 10/31/14

biotie therapies oyj (BTH1V) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biotie therapies oyj (BTH1V) Key Developments

Biotie Announces Top-Line Results from Nepicastat (SYN117) Study in Cocaine Dependence

Biotie Therapies Corp. announced top-line results from a Phase 2 clinical study with nepicastat (SYN117) in cocaine-dependent patients. When compared to placebo, nepicastat did not meet the primary efficacy endpoint of an increased proportion of subjects remaining abstinent from cocaine during the last two weeks of the treatment period. Nepicastat was generally well tolerated in the study. A comprehensive analysis of safety and efficacy data is ongoing. The study enrolled 179 treatment-seeking cocaine-dependent subjects in a randomized, double-blind placebo-controlled trial, in which the duration of drug treatment was 11 weeks. The study was conducted at 10 US clinics specializing in the treatment of drug dependence and was funded by the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health under a Collaborative Research and Development Agreement (CRADA).

Biotie Therapies Corp.(HLSE:BTH1V) added to OMX Nordic Small Cap Index

Biotie Therapies Corp. has been added to OMX Nordic Small Cap Index.

Biotie Announces Start of SYN120 Phase 2A Trial in Parkinson's Disease Dementia

Biotie Therapies Corp. announced the start of the Phase 2a clinical study of SYN120, a 5-HT6/5-HT2A antagonist, in patients with Parkinson's disease dementia (PDD). The study is being funded by The Michael J. Fox Foundation (MJFF). The SYNAPSE study is an 80 patient, Phase 2a, randomized, double-blind, multi-center, placebo-controlled trial in patients with Parkinson's disease dementia. Patients will be randomized 1:1 to placebo or SYN120 dosed once daily over a 16 week treatment period. In addition to assessing safety and tolerability, the main focus of the study is to establish efficacy of SYN120 on cognition using the Cognitive Drug Research (CDR) Computerized Cognition Battery as the primary efficacy endpoint. The study will be conducted by the Parkinson Study Group (PSG) at approximately 12 sites in the United States specializing in cognitive dysfunction in Parkinson's disease. Biotie and the PSG will share responsibility for the design and execution of the study, and top-line results of the study are expected in the second half of 2016. Biotie retains the rights to SYN120 and will be able to use data from the MJFF-funded study for any future regulatory submission. Final preparations are ongoing for an investigator-sponsored Phase 2 study of Biotie's monoclonal anti-VAP-1 antibody BTT1023 in primary sclerosing cholangitis. The BUTEO study, previously expected to commence by the end of 2014, is now expected to start in first quarter 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.19 EUR -0.008

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies
 

Industry Analysis

BTH1V

Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.